First Header Logo Second Header Logo

Xin Ming PhD

Address
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R01CA194064     (MING, XIN)Dec 1, 2015 - Nov 30, 2021
    NIH
    Combination Therapy of OvCA with Oligonucleotides and Photodynamic Therapy
    Role: Principal Investigator

    R21CA267853     (MING, XIN)Dec 10, 2021 - Nov 30, 2023
    NIH
    Targeted Anchoring Ecto-enzyme on Cancer Cell Surface to Enhance Antibody Therapy in Breast Cancer
    Role: Principal Investigator

    R21CA263759     (MING, XIN)Apr 1, 2022 - Mar 31, 2024
    NIH
    Stimuli-responsive Delivery of Ectonucleotidase Inhibitors to Reprogram Immunometabolism in Head and Neck Cancer
    Role: Principal Investigator

    R21DE032183     (MING, XIN)Jul 1, 2022 - Jun 30, 2024
    NIH
    Precise Modulation of Immunometabolism to Boost Antibody Therapy in Oral Cancer
    Role: Principal Investigator

    R21CA286977     (MING, XIN)Mar 1, 2024 - Feb 28, 2026
    NIH/NCI
    ATP-responsive Nanoparticles for Reversal of Immune Evasion in Breast Cancer
    Role Description: In this proposal, we will develop cancer-targeting nanoparticles to deliver small molecule drugs in order to enhance anticancer immunity in treating breast cancer.
    Role: Principle Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Mao C, Yeh S, Fu J, Porosnicu M, Thomas A, Kucera GL, Votanopoulos KI, Tian S, Ming X. Delivery of an ectonucleotidase inhibitor with ROS-responsive nanoparticles overcomes adenosine-mediated cancer immunosuppression. Sci Transl Med. 2022 Jun 08; 14(648):eabh1261. PMID: 35675434.
      Citations:    
    2. Xue G, Wang Z, Zheng N, Fang J, Mao C, Li X, Jin G, Ming X, Lu Y. Elimination of acquired resistance to PD-1 blockade via the concurrent depletion of tumour cells and immunosuppressive cells. Nat Biomed Eng. 2021 Nov; 5(11):1306-1319. PMID: 34725506.
      Citations:    
    3. Mao C, Li F, Zhao Y, Debinski W, Ming X. P-glycoprotein-targeted photodynamic therapy boosts cancer nanomedicine by priming tumor microenvironment. Theranostics. 2018; 8(22):6274-6290. PMID: 30613297.
      Citations:    
    4. Mao C, Qu P, Miley MJ, Zhao Y, Li Z, Ming X. P-glycoprotein targeted photodynamic therapy of chemoresistant tumors using recombinant Fab fragment conjugates. Biomater Sci. 2018 Oct 24; 6(11):3063-3074. PMID: 30298866.
      Citations:    
    5. Suo X, Eldridge BN, Zhang H, Mao C, Min Y, Sun Y, Singh R, Ming X. P-Glycoprotein-Targeted Photothermal Therapy of Drug-Resistant Cancer Cells Using Antibody-Conjugated Carbon Nanotubes. ACS Appl Mater Interfaces. 2018 Oct 03; 10(39):33464-33473. PMID: 30188117.
      Citations:    
    6. Mao C, Zhao Y, Li F, Li Z, Tian S, Debinski W, Ming X. P-glycoprotein targeted and near-infrared light-guided depletion of chemoresistant tumors. J Control Release. 2018 09 28; 286:289-300. PMID: 30081143.
      Citations:    
    7. Zhao Y, Li F, Mao C, Ming X. Multiarm Nanoconjugates for Cancer Cell-Targeted Delivery of Photosensitizers. Mol Pharm. 2018 07 02; 15(7):2559-2569. PMID: 29764120.
      Citations:    
    8. Juliano RL, Wang L, Tavares F, Brown EG, James L, Ariyarathna Y, Ming X, Mao C, Suto M. Structure-activity relationships and cellular mechanism of action of small molecules that enhance the delivery of oligonucleotides. Nucleic Acids Res. 2018 02 28; 46(4):1601-1613. PMID: 29361039.
      Citations:    
    9. Dong C, Ming X, Ye Z, Wang P, Wang L, Li Z, Pan B. Icariside II Attenuates Chronic Hydrocephalus in an Experimental Subarachnoid Hemorrhage Rat Model. J Pharm Pharm Sci. 2018; 21(1):318-325. PMID: 30070971.
      Citations:    
    10. Wang M, Mao C, Wang H, Ling X, Wu Z, Li Z, Ming X. Molecular Imaging of P-glycoprotein in Chemoresistant Tumors Using a Dual-Modality PET/Fluorescence Probe. Mol Pharm. 2017 10 02; 14(10):3391-3398. PMID: 28813596.
      Citations:    
    11. Li F, Zhao Y, Mao C, Kong Y, Ming X. RGD-Modified Albumin Nanoconjugates for Targeted Delivery of a Porphyrin Photosensitizer. Mol Pharm. 2017 08 07; 14(8):2793-2804. PMID: 28700237.
      Citations:    
    12. Sunwook K, Nussbaum MA, Quandt SA, Laurienti PJ, Arcury TA. Effects of Lifetime Occupational Pesticide Exposure on Postural Control Among Farmworkers and Non-Farmworkers. J Occup Environ Med. 2016 Feb; 58(2):133-9. PMID: 23396438.
      Citations:    
    13. Ming X, Wu L, Carver K, Yuan A, Min Y. Dendritic nanoconjugates for intracellular delivery of neutral oligonucleotides. Nanoscale. 2015 Aug 07; 7(29):12302-6. PMID: 26134311.
      Citations:    
    14. Yuan A, Yang B, Wu J, Hu Y, Ming X. Dendritic nanoconjugates of photosensitizer for targeted photodynamic therapy. Acta Biomater. 2015 Jul; 21:63-73. PMID: 25900441.
      Citations:    
    15. Yuan A, Laing B, Hu Y, Ming X. Direct oligonucleotide-photosensitizer conjugates for photochemical delivery of antisense oligonucleotides. Chem Commun (Camb). 2015 Apr 18; 51(30):6678-80. PMID: 25786195.
      Citations:    
    16. Ming X, Laing B. Bioconjugates for targeted delivery of therapeutic oligonucleotides. Adv Drug Deliv Rev. 2015 Jun 29; 87:81-9. PMID: 25689735.
      Citations:    
    17. Yuan A, Hu Y, Ming X. Dendrimer Conjugates for Light-activated Delivery of Antisense Oligonucleotides. RSC Adv. 2015; 5:35195-35200. PMID: 26146545.
      Citations:    
    18. Chen F, Ming X, Chen X, Gan M, Wang B, Xu F, Wei H. Immunochromatographic strip for rapid detection of Cronobacter in powdered infant formula in combination with silica-coated magnetic nanoparticles separation and 16S rRNA probe. Biosens Bioelectron. 2014 Nov 15; 61:306-13. PMID: 24907538.
      Citations:    
    19. Ming X, Carver K, Wu L. Albumin-based nanoconjugates for targeted delivery of therapeutic oligonucleotides. Biomaterials. 2013 Oct; 34(32):7939-49. PMID: 23876758.
      Citations:    
    20. Juliano RL, Ming X, Nakagawa O. The chemistry and biology of oligonucleotide conjugates. Acc Chem Res. 2012 Jul 17; 45(7):1067-76. PMID: 22353142.
      Citations:    
    21. Ming X, Sato K, Juliano RL. Unconventional internalization mechanisms underlying functional delivery of antisense oligonucleotides via cationic lipoplexes and polyplexes. J Control Release. 2011 Jul 15; 153(1):83-92. PMID: 21571016.
      Citations:    
    22. Nakagawa O, Ming X, Huang L, Juliano RL. Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands. J Am Chem Soc. 2010 Jul 07; 132(26):8848-9. PMID: 20550198.
      Citations:    
    23. Ming X, Alam MR, Fisher M, Yan Y, Chen X, Juliano RL. Intracellular delivery of an antisense oligonucleotide via endocytosis of a G protein-coupled receptor. Nucleic Acids Res. 2010 Oct; 38(19):6567-76. PMID: 20551131.
      Citations:    
    Ming's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (122)
    Explore
    _
    Co-Authors (2)
    Explore
    _
    Similar People (51)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _